This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exelixis' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Exelixis, Inc. (EXEL)

Morgan Stanley Healthcare Conference

September 11, 2012 8:35 am ET


Michael Morrissey - President, Chief Executive Officer


Marshall Urist - Morgan Stanley


Marshall Urist - Morgan Stanley

So, good morning, everyone. Thanks for joining us. I am Marshall Urist, one of the biotech analysts here at Morgan Stanley and just one piece of business before we get started. Any and all of our research disclosures can be found on any piece of our research or on our website and with that, why don’t we jump in.

We are very happy to be here this morning, with Mike Morrissey, CEO of Exelixis, who I am sure many of you know and before we jump in, this is actually supposed to be open Q&A. So if there any question, please raise your hands and there is microphone circulating.

So with that, Mike, thanks for being here this morning, and maybe to start off, I think it might be useful, you guys just obviously completed a successful and large fundraising. So maybe talk about, give a quick overview for people, where things stand and then we will kind of jump in.

Michael Morrissey

Sounds good. So, again, I will be making forward looking statements this morning. So, please see our SEC filings for a description of the risks that we face in our business. So that’s, right. So we have had a very busy summer and certainly going into a very busy fall.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs